Document Type
Presentation
Loading...
Media is loading
Publication Date
5-13-2020
Abstract
This session will cover the high-process of vaccine development in the pharmaceutical sector, specifically examining the development of a DNA-based vaccine against COVID-19. The role of epidemiology in these processes will be emphasized.
Overview & Objectives
To understand:
- Vaccines: the Research and Development Process
- Development & Testing of a DNA-based COVID-19 Vaccine
- How epidemiology is involved in the pharma R&D process for vaccines
- Information on therapeutic R & D, great vaccinologists, etc.
Recommended Citation
Herring, MPH, Timothy, "COVID-19: Pharmaceutical Vaccine Development – General Process & Focus on a DNA-based Vaccine" (2020). COVID-19: Spread the Science, not the Virus Seminar Series. Paper 5.
https://jdc.jefferson.edu/covid-19-ssnv/5
Language
English
COinS
Comments
Mr. Herring has over 30 years biomedical science experience, of which the last 25 years has been in epidemiology. In the last 12 years he has worked in pharmaceutical vaccine & drug epidemiology and clinical research and development. Most recently, at Inovio Pharmaceuticals, Inc. he has been supporting development programs for DNA medicines and vaccines against HPV-induced pre-cancers and cancers, COVID-19, Ebola, Zika, MERS, Lassa, Hepatitis B, etc. Earlier while at Merck, he provided support primarily in early development of several prophylactic vaccine programs including those for C. difficile, cytomegalovirus (CMV), dengue fever, and chikungunya.
Prior to work in the pharmaceutical sector, Mr. Herring provided epidemiology services in the consulting sector and in two state health departments. That work included assessment of the health effects of environmental pollutants, communicable disease control and prevention, and cancer research. He has worked on pandemic preparedness, West Nile Virus emergence response, and zoonotic infection epidemic response.
He has co-authored a number of publications and presentations, including those on Inovio’s VGX-3100 DNA medicine for cervical high-grade squamous intraepithelial lesions (HSIL) (i.e. precancer) treatment ground-breaking phase 2b clinical trial results, and earlier on Onchocerca volvulus (the parasite causing river blindness) immunology, Lyme disease, exposure assessment of Thimerosol mercury, and influenza patient-reported outcomes. His Master of Public Health degree in Epidemiology and Bachelor of Science Degree in Natural Science (Biology/Mathematics) are from the University of Alabama at Birmingham.
Presentation: 1:00:36